Medical Condition News

RSS

Vaccinex receives FDA clearance to initiate VX15/2503 Phase 1 clinical trial in advanced solid tumors

Vaccinex, Inc. announced today that it has received clearance from FDA and will initiate a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of therapeutic antibody candidate VX15/2503 in cancer patients with advanced solid tumors.

5 Jan 2011

FDA approves Gore's C3 Delivery System to deploy EXCLUDER AAA Endoprosthesis

W. L. Gore & Associates (Gore) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market the GORE® C3 Delivery System to deploy the GORE® EXCLUDER® AAA Endoprosthesis as a minimally invasive treatment for patients suffering from an abdominal aortic aneurysm (AAA).

5 Jan 2011

Increased amounts of MMP-1 enzyme may explain preeclampsia symptoms in pregnant women

Virginia Commonwealth University School of Medicine researchers have found that a significant increase of an enzyme in the blood vessels of pregnant women with preeclampsia may explain some of the symptoms associated with the condition, including hypertension, swelling and protein in the urine.

5 Jan 2011

Diet low in micronutrients can contribute to metabolic syndrome

Results of an epidemiological study conducted by researchers at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University and the Corporacion Ecuatoriana de Biotecnologia showed that the metabolic syndrome, a condition that increases a person's risk of developing cardiovascular disease and type 2 diabetes, was prevalent in a low-income urban community in Ecuador and that a poor diet low in micronutrients appeared to contribute.

5 Jan 2011

Spectrum submits FUSILEV sNDA for treatment of colorectal cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced it submitted a supplemental New Drug Application with the U.S. Food and Drug Administration (FDA) for a Ready-to-Use formulation of FUSILEV (levoleucovorin) for Injection.

5 Jan 2011

Dutch scientists provide new insights into intestinal cancer through plant study

Dutch scientists have gained important new insights into intestinal cancer from studying a plant. The disease is called Peutz-Jeghers Syndrome, a hereditary disorder where people develop intestinal polyps that turn into malignant tumors.

5 Jan 2011

FDA lifts clinical hold on Hemispherx's Alferon LDO Phase II study for influenza prevention

Hemispherx Biopharma, Inc. announced today that the Food and Drug Administration (FDA) has lifted a clinical hold on its Phase II, double-blind, adaptive-design, randomized, placebo-controlled, dose-ranging study of Alferon® LDO [oral interferon alfa-n3 (human leukocyte derived)] for the prevention and treatment of influenza.

5 Jan 2011

Pico-Tesla announces expansion of Magneceutical Phase III trail for Parkinson's disease

Pico-Tesla, The Magneceutical Company, announced that it has expanded its ongoing Phase III pivotal clinical trial by adding three Principal Investigators, including two university-affiliated clinicians: one in Denver; and one in Tampa.

5 Jan 2011

Tiny light source and sensors in endoscope may detect esophageal cancer more accurately

A tiny light source and sensors at the end of an endoscope may provide a more accurate way to identify pre-cancerous cells in the lining of the esophagus.

4 Jan 2011

FDA approves ImmunoCellular Therapeutics IND amendment for ICT-107 Phase II clinical trial

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) amendment to conduct a Phase II clinical trial in the U.S. of ICT-107, the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM).

4 Jan 2011

TRPM2 in pancreatic beta-cells may control insulin secretion levels

The research group led by professor Makoto Tominaga and Dr. Kunitoshi Uchida, National institute for Physiological Sciences, found TRPM2 ion channel in pancreatic beta-cells is important for insulin secretion stimulated by glucose and gastrointestinal hormone secreted after food intake. Their finding was reported in Diabetes.

4 Jan 2011

Clinicians rely upon analgesics and surgery; overlook exercise and weight loss for OA patients

New research found clinicians who care for patients with osteoarthritis (OA) are likely not following standard care guidelines that are based on current medical evidence. Researchers noted physicians were prescribing medications for pain and inflammation, or opting for surgical interventions rather than recommending weight loss plans or exercise programs to OA patients.

4 Jan 2011

CAMFT launches new searchable online directory for counselors and therapists

Taking control of your mental health and finding the support you need just got easier for Californians thanks to a new searchable online directory, CounselingCalifornia.com. The free service created by the California Association of Marriage and Family Therapists (CAMFT) addresses a significant hurdle for Californians looking for counselors and therapists.

4 Jan 2011

Star Scientific develops moist snuff tobacco product with low carcinogenic levels

Star Scientific, Inc. reports that it has successfully developed a moist snuff tobacco product that has extremely low levels of carcinogens -- much lower than any snuff products currently in the marketplace. This new product has levels of tobacco-specific nitrosamines (TSNAs) -- recognized by scientists worldwide as one of the most powerful cancer-causing agents in tobacco leaf and smoke -- below 20 parts per billion (nanograms-per-gram moist weight, as used) in initial testing.

4 Jan 2011

Past smoking history does not affect RA patient's response to treatments

Patients with early rheumatoid arthritis (RA) who are current smokers were less likely to achieve good response to methotrexate (MTX) and tumor necrosis factor (TNF) inhibitors than those who never smoked. The study by researchers from Sweden also found that RA patients who smoked in the past did not experience a lower response to these therapies. Results of the 10-year study appear in the January 2011 issue of Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR).

4 Jan 2011

Isis commences ISIS-EIF4ERx Phase 2 studies in non-small cell lung cancer and prostate cancer

Isis Pharmaceuticals, Inc. announced the initiation of two Phase 2 studies of ISIS-EIF4ERx in patients with non-small cell lung cancer and prostate cancer. These studies are part of Isis' broad Phase 2 development program designed to evaluate ISIS-EIF4ERx in multiple types of cancer. ISIS-EIF4ERx targets eukaryotic initiation factor-4E (eIF-4E), a traditionally "undruggable" target that is thought to promote tumor growth and metastasis in many cancers.

4 Jan 2011

STAAR Surgical exceeds 200,000 Visian ICL global implants

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced that the worldwide total number of Visian® ICL implants in patients has exceeded 200,000. Since 1994, STAAR's Implantable Collamer® Lenses (ICLs) have been used in refractive eye surgery as an alternative to LASIK. Manufactured with STAAR's proprietary Collamer material, Visian ICLs provide a safe and effective alternative in the permanent correction of myopia, hyperopia, and in the case of the Toric ICL, astigmatism.

4 Jan 2011

New research finds pattern for detecting 'false-positive' ANA results

The presence of antinuclear antibodies (ANA) indicates the possibility of autoimmunity and the indirect immunofluorescence (IIF) assay on HEp-2 cells is the standard blood test (ANA-HEp-2) used to detect ANA. However, studies have shown that a "false-positive" ANA test occurs in up to 13% of healthy individuals. In such cases the test detects the presence of autoantibodies that apparently are not associated with autoimmunity.

4 Jan 2011

People fail to understand consequences of social trauma felt by bullied victims

Taunted, harassed, and pushed to a deadly breaking point. Last year, stories of teen bullying brought to life the heartbreaking consequences of young lives cut short by ruthless and unchecked behavior. While recent media coverage of these violent acts has increased national awareness of bullying's deadly consequences, it has done little to stop it from happening.

4 Jan 2011

Encouraging results from exon skipping gene-based therapy study for DMD

Scientists at Royal Holloway, University of London have reported encouraging results in a new gene-based therapy for Duchenne Muscular dystrophy (DMD) which at present has no known cure and affects one in 3,000 young boys.

4 Jan 2011

Medical Condition News

Vaccinex receives FDA clearance to initiate VX15/2503 Phase 1 clinical trial in advanced solid tumors

FDA approves Gore's C3 Delivery System to deploy EXCLUDER AAA Endoprosthesis

Increased amounts of MMP-1 enzyme may explain preeclampsia symptoms in pregnant women

Diet low in micronutrients can contribute to metabolic syndrome

Spectrum submits FUSILEV sNDA for treatment of colorectal cancer

Dutch scientists provide new insights into intestinal cancer through plant study

FDA lifts clinical hold on Hemispherx's Alferon LDO Phase II study for influenza prevention

Pico-Tesla announces expansion of Magneceutical Phase III trail for Parkinson's disease

Tiny light source and sensors in endoscope may detect esophageal cancer more accurately

FDA approves ImmunoCellular Therapeutics IND amendment for ICT-107 Phase II clinical trial

TRPM2 in pancreatic beta-cells may control insulin secretion levels

Clinicians rely upon analgesics and surgery; overlook exercise and weight loss for OA patients

CAMFT launches new searchable online directory for counselors and therapists

Star Scientific develops moist snuff tobacco product with low carcinogenic levels

Past smoking history does not affect RA patient's response to treatments

Isis commences ISIS-EIF4ERx Phase 2 studies in non-small cell lung cancer and prostate cancer

STAAR Surgical exceeds 200,000 Visian ICL global implants

New research finds pattern for detecting 'false-positive' ANA results

People fail to understand consequences of social trauma felt by bullied victims

Encouraging results from exon skipping gene-based therapy study for DMD

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News